Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : Sny crawled date : 2022 - 02 - 18 save search
Global Bladder Cancer Drug Market (2021 to 2026) - Unhygienic Workplace Exposure and Increase in Smoking Habits is Driving Growth
Published: 2022-02-18 (Crawled : 21:00) - prnewswire.com
JNJ | News | $150.09 0.65% 4.9M
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 600K
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $47.72 1.21% 1.1M
|
Health Technology
| Email alert
Add to watchlist
bladder cancer drug work cancer drug cancer growth bladder
$26.7 Billion Adult Vaccine Market Outlook, 2027 Featuring Key Players - GSK, Merck & Co, Sanofi Pasteur, Pfizer, and CSL Limited
Published: 2022-02-18 (Crawled : 19:00) - prnewswire.com
SNY | News | $47.72 1.21% 1.1M
|
Health Technology
| Email alert
Add to watchlist
GSK | News | $41.165 1.42% 1.3M
|
Health Technology
| Email alert
Add to watchlist
PFE | News A | $26.29 0.11% 14M
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 600K
|
Health Technology
| Email alert
Add to watchlist
GLAXF | News | $20.305 630
|
Health Technology
| Email alert
Add to watchlist
vaccine
OSE Immunotherapeutics Announces Appointment of Alexandre Lebeaut as an Independent Member of the Board of Directors
Published: 2022-02-18 (Crawled : 18:00) - globenewswire.com
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: -0.23%
H: 0.0%
C: -6.31%
SNY | News | $47.72 1.21% 1.1M
|
Health Technology
|
| O: -0.47%
H: 0.77%
C: -0.23%
ces therapeutics
Sanofi, Regeneron Suffer Rare Dupixent Flop in CSU
Published: 2022-02-18 (Crawled : 16:00) - biospace.com/
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: -0.23%
H: 0.0%
C: -6.31%
SNY | News | $47.72 1.21% 1.1M
|
Health Technology
|
| O: -0.47%
H: 0.77%
C: -0.23%
rare dupixent
With Market Size Valued at $6.5 Billion by 2026, it`s a Healthy Outlook for the Global Throat Lozenges Market
Published: 2022-02-18 (Crawled : 16:00) - prnewswire.com
RBGPF | News | $52.06 4.8K
|
Consumer Non-Durables
|
| O: 3.87%
H: 0.0%
C: -3.44%
GLAXF | News | $20.305 630
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -2.14%
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: -0.23%
H: 0.0%
C: -6.31%
RBGLY | News | $10.59 850K
|
Manufacturing
|
| O: 3.3%
H: 0.4%
C: -0.97%
GSK | News | $41.165 1.42% 1.3M
|
Health Technology
|
| O: -0.46%
H: 0.46%
C: -0.19%
SNY | News | $47.72 1.21% 1.1M
|
Health Technology
|
| O: -0.47%
H: 0.77%
C: -0.23%
health
BioSpace Movers & Shakers, Feb. 18
Published: 2022-02-18 (Crawled : 14:00) - biospace.com/
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: -0.23%
H: 0.0%
C: -6.31%
JNJ | News | $150.09 0.65% 4.9M
|
Health Technology
|
| O: -0.73%
H: 0.23%
C: -0.98%
VXRT | News | $0.7221 -5.3% 1.4M
|
Health Technology
|
| O: 0.0%
H: 2.95%
C: 0.21%
SNY | News | $47.72 1.21% 1.1M
|
Health Technology
|
| O: -0.47%
H: 0.77%
C: -0.23%
BMRN | $91.93 2.73% 850K
|
Health Technology
|
| O: -1.89%
H: 1.47%
C: -4.21%
ALEC | $5.33 3.1% 93K
|
Health Technology
|
| O: -0.37%
H: 3.37%
C: 2.06%
space spac
Azurity Pharmaceuticals Announces Richard Blackburn as New CEO
Published: 2022-02-18 (Crawled : 12:00) - biospace.com/
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: -0.23%
H: 0.0%
C: -6.31%
SNY | News | $47.72 1.21% 1.1M
|
Health Technology
|
| O: -0.47%
H: 0.77%
C: -0.23%
als ces new ceo ceo
Update on ongoing Dupixent® (dupilumab) chronic spontaneous urticaria Phase 3 program
Published: 2022-02-18 (Crawled : 09:00) - biospace.com/
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: -0.23%
H: 0.0%
C: -6.31%
SNY | News | $47.72 1.21% 1.1M
|
Health Technology
|
| O: -0.47%
H: 0.77%
C: -0.23%
REGN | News | $910.71 1.17% 150K
|
Health Technology
|
| O: -0.78%
H: 1.76%
C: -1.08%
dupixent ongoing program phase 3 urticaria
BioArctic continues to build its commercial organization
Published: 2022-02-18 (Crawled : 08:00) - prnewswire.com
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: -0.23%
H: 0.0%
C: -6.31%
JNJ | News | $150.09 0.65% 4.9M
|
Health Technology
|
| O: -0.73%
H: 0.23%
C: -0.98%
SNY | News | $47.72 1.21% 1.1M
|
Health Technology
|
| O: -0.47%
H: 0.77%
C: -0.23%
commercialization
Regeneron and Sanofi Provide Update on Ongoing Dupixent® (dupilumab) Chronic Spontaneous Urticaria Phase 3 Program
Published: 2022-02-18 (Crawled : 07:00) - prnewswire.com
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: -0.23%
H: 0.0%
C: -6.31%
SNY | News | $47.72 1.21% 1.1M
|
Health Technology
|
| O: -0.47%
H: 0.77%
C: -0.23%
REGN | News | $910.71 1.17% 150K
|
Health Technology
|
| O: -0.78%
H: 1.76%
C: -1.08%
dupixent ongoing program phase 3 urticaria
Gainers vs Losers
| 86% | 14% |
Top 10 Gainers
MTTR | News M | $4.56 162.07% 21M
|
AGBA | $2.74 119.2% 52M
|
Finance
CZOO | $9.07 81.76% 22M
|
EDBL | News | $6.56 74.47% 1.8M
|
MTC | $2.21 41.67% 5.6M
|
Technology Services
OPRT | News | $3.12 38.67% 11M
|
Finance
PALI | $6.59 33.67% 23M
|
Manufacturing
VNRX | $0.7989 33.15% 3.2M
|
Health Technology
MLEC | $1.81 29.29% 2.8M
|
n/a
BTCM | $3.45 27.78% 640K
|
Arts, Entertainment, and Recrea...
Your saved searches
Save your searches and get alerts when important news are released.